Sex: F
Vaccine: COVID19, COVID19
Symptoms: Anti-aquaporin-4 antibody, Antibody test, Antineutrophil cytoplasmic antibody, Antinuclear antibody, COVID-19
Clinical narrative: PCR for SARS-CoV-2 was positive; COVID-19; This is a literature report.  A 41-year-old female patient received BNT162b2 (BNT162B2), in Apr2021 as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; COVID-19 vaccine (COVID-19 VACCINE), as dose 1, single) and as dose 2, single) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (hospitalization, medically significant), outcome "unknown", described as "PCR for SARS-CoV-2 was positive"; COVID-19 (hospitalization, medically significant), outcome "unknown". The patient underwent the following laboratory tests and procedures: Anti-aquaporin-4 antibody: Negative; Antibody test: Negative; Antineutrophil cytoplasmic antibody: Negative; Antinuclear antibody: Negative; Fundoscopy: normal; anti-nuclear antigen: Negative; Negative; Magnetic resonance imaging: abnormal T2 signal and enhancement, notes: of the intracanalicular right optic nerve without nerve sheath enhancement or fat stranding; Magnetic resonance imaging head: was normal; Mycobacterium tuberculosis complex test: Negative; Neurological examination: normal; Ophthalmological examination: 258, notes: units:um; 313, notes: units:um; 258, notes: units:um; 121, notes: units:um; SARS-CoV-2 test: Positive; Treponema test: Negative; Visual acuity tests: 3 feet OD and 20/20 OS,, notes: a right rAPD, and a central scotoma to confrontation; improved to 20/40; Visual field tests: some central points of, notes: depression. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: Patient 2 A 41-year-old woman, vaccinated against SARS-CoV-2 in April 2021, presented for painful vision loss OD in January 2022. She reported pain OD, followed 2-3 days later by ipsilateral vision loss. Examination revealed visual acuities of counting fingers at 3 feet OD and 20/20 OS, a right rAPD, and a central scotoma to confrontation. Mildly hyperemic optic disc edema was observed OD with otherwise normal fundi. She had no additional neurologic symptoms and a normal neurologic examination. Orbital MRI revealed abnormal T2 signal and enhancement of the intracanalicular right optic nerve without nerve sheath enhancement or fat stranding. Brain MRI was normal. Spinal imaging and lumbarpuncture were deferred. Serum AQP4 and MOG antibodies, anti-nuclear antigen, nuclear antibody panel, antineutrophilic cytoplasmic antigen, and testing for syphilis, sarcoid, and tuberculosis were negative.She was admitted and reported an isolated sore throat. PCR for SARS-CoV-2 was positive. She received intravenous methylprednisolone 1 g/day for 3 days, then oral prednisone tapered according to the Optic Neuritis Treatment Trial (ONTT). Her pain resolved 2 days after steroid initiation, and her visual acuity improved to 20/70 after 3 days. Ten weeks after symptom onset, visual acuity had improved to 20/40 with some central points of depression on automated visual field testing. Her optic disc appearance had normalized. the 6 previously published cases described patients who presented before the development of SARS-CoV-2 vaccines, and none mention vaccination within 4 weeks of optic neuritis. Vaccination is unlikely to have played a causal role in SARS-CoV-2 parainfectious optic neuritis in any of the patients in our series. Patient 1 was unvaccinated, Patient 2 had received a Pfizer mRNA booster 2 months before her optic neuritis, and Patient 3 developed optic neuritis 4 months after Pfizer mRNA vaccination. Vaccination status was not uniformly reported in the literature, although 5 of; Sender's Comments: The efficacy of a drug varies from patient to patient and can be affected by different factors; however, a contributory role of the suspect product to the reported event Drug ineffective and COVID 19 cannot be ruled out.,Linked Report(s) : US-PFIZER INC-202300450659 Same article/drug/event and different patient;